financetom
Business
financetom
/
Business
/
--International General Insurance Raises Quarterly Dividend 150% to $0.025 Per Share; Payable June 20 to Shareholders on June 3
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
--International General Insurance Raises Quarterly Dividend 150% to $0.025 Per Share; Payable June 20 to Shareholders on June 3
May 15, 2024 7:37 AM

10:08 AM EDT, 05/15/2024 (MT Newswires) --

Price: 14.73, Change: +0.26, Percent Change: +1.80

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
CASI Says FDA Clears New Drug Application for Antibody-Mediated Rejection Treatment; Shares Rise
CASI Says FDA Clears New Drug Application for Antibody-Mediated Rejection Treatment; Shares Rise
Aug 4, 2025
09:26 AM EDT, 08/04/2025 (MT Newswires) -- CASI Pharmaceuticals ( CASI ) said Monday the US Food and Drug Administration has cleared its investigational new drug application for CID-103, a potential treatment for adults with active and chronic active renal allograft antibody mediated rejection. The phase 1 trial will assess the tolerability and efficacy of CID-103 in patients with disease,...
Sonnet BioTherapeutics Expanding Ovarian Cancer Drug Study
Sonnet BioTherapeutics Expanding Ovarian Cancer Drug Study
Aug 4, 2025
09:25 AM EDT, 08/04/2025 (MT Newswires) -- Sonnet BioTherapeutics ( SONN ) said Monday it plans to expand its ongoing phase 1b/2a trial of SON-1010 plus atezolizumab in patients with platinum-resistant ovarian cancer. The company said two of three patients at the current top maintenance dose of SON-1010 had a 'significant tumor response.' Based on the 'strong safety profile,' a...
NYSE names public policy veteran Bryan Daniel as president of NYSE Texas
NYSE names public policy veteran Bryan Daniel as president of NYSE Texas
Aug 4, 2025
Aug 4 (Reuters) - The New York Stock Exchange on Monday named Bryan Daniel as the president of NYSE Texas, adding political experience to its leadership ranks as it seeks to expand in the state and counter rivals. His background in public policy could be key as NYSE works to strengthen its presence in a state that hosts the largest...
Copyright 2023-2026 - www.financetom.com All Rights Reserved